Lumos Diagnostics Holdings Limited (LDXHF) Research
Lumos Diagnostics Holdings Limited operates as a contract research and development firm dedicated to creating and commercializing rapid, point-of-care (POC) diagnostic solutions. The company primarily focuses on identifying and managing infectious diseases, with a market presence in both the United States and Australia. Its product line includes FebriDx, an immediate diagnostic tool capable of differentiating between viral and bacterial respiratory infections; ViraDx, a single-test solution for detecting influenza A, influenza B, and COVID-19; and CoviDx, a quick antigen test specifically for COVID-19. Additionally, Lumos provides various reader devices, such as desktop, disposable, and its exclusive Lumos Leelu models. The company was established in 2004 and is headquartered in Melbourne, Australia.
Market snapshot
- Symbol
- LDXHF
- Price
- $0.08
- Day change
- 0.00%
- Market cap
- $61.5M
- P/E ratio
- -6.66x
- 52-week range
- 0.0161-0.24
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Next earnings
- in 2 months
Recent news
- US commercialisation of FebriDx® to be discussed at Lumos Webinar: Thursday, June 11, at 10:30am AEST
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) will host a virtual investor briefing on Thursday, June 11, at 10:30am AEST to provide an update on the...
- Five Below shares fall as tariff assumptions draw focus from earnings beat
Five Below (NASDAQ:FIVE) shares fell about 11% at Thursday's market open, as investors looked past a stronger-than-expected first quarter earnings report...
- FTSE 100 Live: Stocks vacillating, CMC surges, SpaceX to IPO next week
9.21am: FTSE oscillating The FTSE 100 has been in vacillating form this morning, swinging to a 25-point gain and now to a deficit of 10 points at 10,322. ...
Peer companies
Open Lumos Diagnostics Holdings Limited (LDXHF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.